BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35779117)

  • 1. Adult Langerhans cell histiocytosis with thyroid gland involvement: clinical presentation, genomic analysis, and outcome.
    Cai HC; Liu T; Cai H; Duan MH; Li J; Zhou DB; Cao XX
    Ann Hematol; 2022 Sep; 101(9):1925-1929. PubMed ID: 35779117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Langerhans cell histiocytosis in adolescent patients: a single-centre retrospective study.
    Cai HC; Chen J; Liu T; Cai H; Duan MH; Li J; Zhou DB; Cao XX
    Orphanet J Rare Dis; 2022 Jul; 17(1):268. PubMed ID: 35841042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.
    Jouenne F; Chevret S; Bugnet E; Clappier E; Lorillon G; Meignin V; Sadoux A; Cohen S; Haziot A; How-Kit A; Kannengiesser C; Lebbé C; Gossot D; Mourah S; Tazi A
    Eur Respir J; 2020 Feb; 55(2):. PubMed ID: 31806714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF gene mutations in synchronous papillary thyroid carcinoma and Langerhans cell histiocytosis co-existing in the thyroid gland: a case report and literature review.
    A Al Hamad M; Albisher HM; Al Saeed WR; Almumtin AT; Allabbad FM; A Shawarby M
    BMC Cancer; 2019 Feb; 19(1):170. PubMed ID: 30795755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of thyroid involvement in children and adult Langerhans cell histiocytosis: An underestimated endocrine manifestation.
    Li Y; Chang L; Chai X; Liu H; Yang H; Xia Y; Huo L; Zhang H; Li N; Lian X
    Front Endocrinol (Lausanne); 2022; 13():1013616. PubMed ID: 36246871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
    Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement.
    Yao JF; Wang D; Ma HH; Lian HY; Zhang L; Wang TY; Li ZG; Jiang J; Cui L; Zhang R
    J Pediatr; 2022 May; 244():194-202.e5. PubMed ID: 35065150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.
    Alayed K; Medeiros LJ; Patel KP; Zuo Z; Li S; Verma S; Galbincea J; Cason RC; Luthra R; Yin CC
    Hum Pathol; 2016 Jun; 52():61-7. PubMed ID: 26980021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features, genomic profiling, and outcomes of adult patients with unifocal Langerhans cell histiocytosis.
    Lang M; Cai HC; Lin H; Chang L; Dai JW; Chen J; Duan MH; Zhou DB; Goyal G; Cao XX
    Orphanet J Rare Dis; 2023 Nov; 18(1):372. PubMed ID: 38037140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating cell-free BRAF
    Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
    Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the BRAF and MAP2K1 mutations in patients with Langerhans cell histiocytosis in Japan.
    Hayase T; Saito S; Shioda Y; Imamura T; Watanabe K; Ohki K; Yoshioka T; Oh Y; Kawahara Y; Niijima H; Imashuku S; Morimoto A
    Int J Hematol; 2020 Oct; 112(4):560-567. PubMed ID: 32654047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
    Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
    Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
    Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
    Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
    Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Langerhans cell histiocytosis of cervical lymph nodes in adult patients with papillary thyroid carcinoma: A report of two cases and review of the literature.
    Maraqa B; Al-Ashhab M; Kamal N; El Khaldi M; Sughayer M
    Autops Case Rep; 2021; 11():e2021253. PubMed ID: 34307217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival.
    Bhatia P; Singh M; Sharma M; Sharma A; Kakkar N; Radhika S; Trehan A; Bansal D
    Blood Cells Mol Dis; 2020 May; 82():102356. PubMed ID: 32171112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.